Investment Thesis
SCYNEXIS exhibits exceptional revenue growth (+449.9% YoY) but this growth quality is severely compromised by a near-zero 0.3% gross margin, substantial operating losses (-$16.1M), and significant negative operating cash flow (-$5.3M). The company is burning cash despite topline growth, with limited runway given $34.6M debt obligations and an inability to cover interest expenses from operations.
Strengths
- Exceptional revenue growth of 449.9% YoY demonstrates strong market demand or successful product launch
- Strong liquidity position with 7.04x current ratio and $21.3M cash enabling operational flexibility
- Moderate leverage at 0.70x Debt/Equity provides some financial stability and borrowing capacity
Risks
- Critically low gross margin of 0.3% indicates minimal profitability per revenue dollar and potential unsustainable business model
- Negative operating cash flow of -$5.3M despite high revenue suggests poor unit economics and cash burn incompatible with long-term viability
- Operating losses of -$16.1M combined with -39.9x interest coverage ratio indicates inability to service debt obligations from operations
- Estimated cash runway of 4 quarters at current burn rate creates significant refinancing risk
- Pharmaceutical sector execution risk with no margin of safety given current financial structure
Key Metrics to Watch
- Gross margin trend - must improve substantially from current 0.3% level
- Operating cash flow - critical indicator of whether growth translates to sustainable business
- Cash balance depletion rate - monitor runway to determine refinancing needs
- Operating loss trajectory - path to profitability is essential for viability
Financial Metrics
Revenue
20.6M
Net Income
-8.6M
EPS (Diluted)
$-0.17
Free Cash Flow
-5.3M
Total Assets
59.0M
Cash
21.3M
Profitability Ratios
Gross Margin
0.3%
Operating Margin
-78.0%
Net Margin
-41.8%
ROE
-17.4%
ROA
-14.6%
FCF Margin
-25.6%
Balance Sheet & Liquidity
Current Ratio
7.04x
Quick Ratio
7.04x
Debt/Equity
0.70x
Debt/Assets
16.4%
Interest Coverage
-39.89x
Long-term Debt
34.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T14:27:24.100288 |
Data as of: 2025-12-31 |
Powered by Claude AI